These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31205913)

  • 1. The relationship between preliminary efficacy and prognosis after first-line
    Chen D; Chu T; Chang Q; Zhang Y; Xiong L; Qiao R; Teng J; Han B; Zhong R
    Ann Transl Med; 2019 May; 7(9):195. PubMed ID: 31205913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy 
in Advanced NSCLC Patients with EGFR Mutations].
    Chen M; Xu Y; Zhao J; Zhong W; Wang M
    Zhongguo Fei Ai Za Zhi; 2019 Feb; 22(2):99-104. PubMed ID: 30827326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
    Su PL; Chen CW; Wu YL; Lin CC; Su WC
    Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced
    He ZY; Li MF; Lin JH; Lin D; Lin RJ
    Cancer Manag Res; 2019; 11():2129-2138. PubMed ID: 30936745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.
    Zhang Y; Zeng L; Zhang X; Li Y; Liu L; Xu Q; Yang H; Jiang W; Lizaso A; Qiu L; Hou T; Liu J; Peng L; Yang N
    BMC Med; 2021 Oct; 19(1):245. PubMed ID: 34663309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
    Takeda M; Okamoto I; Nakagawa K
    J Thorac Oncol; 2014 Feb; 9(2):200-4. PubMed ID: 24419417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
    Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
    Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
    Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
    Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations.
    Xu J; Zhang X; Yang H; Ding G; Jin B; Lou Y; Zhang Y; Wang H; Han B
    Oncotarget; 2016 Oct; 7(42):68442-68448. PubMed ID: 27637087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    Kogure Y; Saka H; Oki M; Saito TI; Ahmed SN; Kitagawa C; Imaizumi K
    PLoS One; 2015; 10(8):e0135393. PubMed ID: 26262682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations.
    Salvador-Coloma C; Lorente D; Palanca S; Simarro J; Mancheño N; Sandoval J; Lahoz A; Juan Ó
    J Thorac Dis; 2018 Mar; 10(3):1386-1393. PubMed ID: 29707288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI.
    Lin L; Zhao J; Hu J; Huang F; Han J; He Y; Cao X
    J Cancer; 2018; 9(3):528-534. PubMed ID: 29483958
    [No Abstract]   [Full Text] [Related]  

  • 20. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.
    Gao G; Ren S; Li A; Xu J; Xu Q; Su C; Guo J; Deng Q; Zhou C
    Int J Cancer; 2012 Sep; 131(5):E822-9. PubMed ID: 22161771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.